Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RDY, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Active01 Cream | Common Warts | Phase 2 · NCT02798419 | Completed |
| DFD05 Cream | Common Warts | Phase 2 · NCT02798419 | Completed |
| Denileukin Diftitox (E7777) | Epithelial Ovarian Cancer | Phase 1/2 · NCT05200559 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not RDY's own candidates): Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RDY holds $81.4B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RDY files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RDY and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →